Blood Reviews

Article	Citations
Interplay between platelets and coagulation	188
Targeting MCL-1 in hematologic malignancies: Rationale and progress	140
Coagulation and anticoagulation in COVID-19	140
Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system	128
Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes	114
The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysis	104
Platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis: Potential role of antiplatelet agents	98
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions	82
A review of FLT3 inhibitors in acute myeloid leukemia	77
Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved	72
Coagulopathy and sepsis: Pathophysiology, clinical manifestations and treatment	71
The looming storm: Blood and cytokines in COVID-19	68
When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities	59
COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research	56
Understanding terminal erythropoiesis: An update on chromatin condensation, enucleation, and reticulocyte maturation	53
Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directions	53
Current state and next-generation CAR-T cells in multiple myeloma	53
Illness and prognostic understanding in patients with hematologic malignancies	48
Hematopoietic versus leukemic stem cell quiescence: Challenges and therapeutic opportunities	46
Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies	43
Inherited thrombocytopenias: an updated guide for clinicians	43
Current and emerging strategies for management of myelodysplastic syndromes	40
Discussing investigational AAV gene therapy with hemophilia patients: A guide	40
Second primary malignancies in multiple myeloma: A review	38
Complement activation in COVID-19 and targeted therapeutic options: A scoping review	36

IKZF1 alterations in acute lymphoblastic leukemia: The good, the bad and the ugly	35
Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature	34
Optimising prophylaxis in haemophilia A: The ups and downs of treatment	34
Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies	33
Targeting the gut microbiome: An emerging trend in hematopoietic stem cell transplantation	31
A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management	29
CLL update 2022: A continuing evolution in care	28
Immune thrombocytopenia: A review of upfront treatment strategies	28
Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options	28
The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag	28
Heterogeneity of congenital afibrinogenemia, from epidemiology to clinical consequences and management	28
It takes two to thrombosis: Hemolysis and complement	27
Hemophilia treatment in 2021: Choosing the”optimal” treatment using an integrative, patient-oriented approach to shared decision-making between patients and clinicians	27
Metabolic regulation of the bone marrow microenvironment in leukemia	27
The critical roles of iron during the journey from fetus to adolescent: Developmental aspects of iron homeostasis	26
l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: Hype or hope?	26
Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: Limitations of predictive models	26
Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option	26
Therapeutic strategies in low and high-risk MDS: What does the future have to offer?	26
Transfusion-related acute lung injury (TRALI): Potential pathways of development, strategies for prevention and treatment, and future research directions	26
Ex vivo expansion of hematopoietic stem cells: Finally transitioning from the lab to the clinic	26
Revving the CAR – Combination strategies to enhance CAR T cell effectiveness	25
Determinants of severity in sickle cell disease	24
A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers	24
Hypereosinophilic syndromes – An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment	23
Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?	23
Hormonal replacement therapy in adolescents and young women with chemo- or radio-induced premature ovarian insufficiency: Practical recommendations	23
Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways	23
Magnesium: The overlooked electrolyte in blood cancers?	22
A clandestine culprit with critical consequences: Benzene and acute myeloid leukemia	22
Gut dysbiosis, endotoxemia and clotting activation: A dangerous trio for portal vein thrombosis in cirrhosis	22
Use of molecularly-cloned haematopoietic growth factors in persons exposed to acute high-dose, high-dose rate whole-body ionizing radiations	21
A review on how to do hematology consults during COVID-19 pandemic	21
Artificial intelligence in hematological diagnostics: Game changer or gadget?	21
Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap	21
AML and the art of remission maintenance	20
A new frontier in Fanconi anemia: From DNA repair to ribosome biogenesis	20
The clinical implications of clonal hematopoiesis in hematopoietic cell transplantation	19
Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity	19
Revisiting Richter transformation in the era of novel CLL agents	19
Targeting cereblon in hematologic malignancies	19
Diagnosis of infectious diseases in immunocompromised hosts using metagenomic next generation sequencing-based diagnostics	18
Targeting health-related quality of life in patients with myelodysplastic syndromes – Current knowledge and lessons to be learned	18
Advances in the management of TTP	18
Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold?	18
The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responses	17
Getting blood out of a stone: Identification and management of patients with poor hematopoietic cell mobilization	17
Cardiovascular and haematological pathology in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): A role for viruses	17
The diagnostic challenges of cardiac amyloidosis: A practical approach to the two main types	17
Combining post-transplant cyclophosphamide with antithymocyte globulin for graft-versus-host disease prophylaxis in hematological malignancies	17

Health related quality of life in children with sickle cell disease: A systematic review and meta-analysis	17
The recipe for TACO: A narrative review on the pathophysiology and potential mitigation strategies of transfusion-associated circulatory overload	16
PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias	16
Follicular lymphoma: The long and winding road leading to your cure?	16
Is microchimerism a sign of imminent disease recurrence after allogeneic hematopoietic stem cell transplantation? A systematic review of the literature	16
Deciphering the messages carried by extracellular vesicles in hematological malignancies	16
Arterial thrombosis in antiphospholipid syndrome (APS): Clinical approach and treatment. A systematic review	16
Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency	16
Loss of 5q in myeloid malignancies – A gain in understanding of biological and clinical consequences	15
Complement in sickle cell disease and targeted therapy: I know one thing, that I know nothing	15
No apparent association between mRNA COVID-19 vaccination and venous thromboembolism	15
Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting.	15
Past, present and future of prognostic scores in follicular lymphoma	14
Thalassaemia in China	14
Fresh frozen plasma transfusion in the neonatal population: A systematic review	14
Decoding DNA methylation in epigenetics of multiple myeloma	14
The extracellular matrix: A key player in the pathogenesis of hematologic malignancies	14
Improving assessment and management of pain in hemophilia: an Italian Delphi consensus statement	13
Free of malignancy but not of fears: A closer look at Damocles syndrome in survivors of hematologic malignancies	13
Assessing the risks of haemolysis as an adverse reaction following the transfusion of ABO incompatible plasma-containing components - A scoping review	13
Neurologic complications of acute myeloid leukemia. Diagnostic approach and therapeutic modalities	13
Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives	13
Optimizing use of L-asparaginase–based treatment of adults with acute lymphoblastic leukemia	12
Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia	12
Maternal and neonatal bleeding complications in relation to peripartum management in hemophilia carriers: A systematic review	12
Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers	12
The future of research in hematology: Integration of conventional studies with real-world data and artificial intelligence	11
Promising role for mesenchymal stromal cells in coronavirus infectious disease-19 (COVID-19)-related severe acute respiratory syndrome?	11
Autonomic nervous system control of multiple myeloma	11
Secondary antibody deficiency in chronic lymphocytic leukemia and non-Hodgkin lymphoma: Recommendations from an international expert panel	11
Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs	11
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium fo	10
Challenging the concept of de novo acute myeloid leukemia: Environmental and occupational leukemogens hiding in our midst	10
Insights on chronic immune thrombocytopenia pathogenesis: A bench to bedside update	10
Understanding the andromeda strain – The role of cytokine release, coagulopathy and antithrombin III in SARS-CoV2 critical illness	10
Hemostatic changes by thrombopoietin-receptor agonists in immune thrombocytopenia patients	10
Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation	10
Back to base pairs: What is the genetic risk for red bloodcell alloimmunization?	10
Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment	10
Infection profiles of different chemotherapy regimens and the clinical feasibility of antimicrobial prophylaxis in patients with DLBCL	10
Post-authorization pharmacovigilance for hemophilia in Europe and the USA: Independence and transparency are keys	10
Endothelial cells: major players in acute myeloid leukaemia	10
Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia	10
Molecular basis of rare congenital bleeding disorders	10
Diagnosis and treatment of lymphomas in the era of epigenetics	9
T time: Emerging and new therapies for peripheral T-cell lymphoma	9
The evolving landscape of gene therapy for congenital haemophilia: An unprecedented, problematic but promising opportunity for worldwide clinical studies	9
Reality check: Real-world evidence to support therapeutic development in hematologic malignancies	9
Insight of fetal to adult hemoglobin switch: Genetic modulators and therapeutic targets	9
Clinical features and treatment strategies for post-transplant and iatrogenic immunodeficiency-associated lymphoproliferative disorders	9
Hematological manifestations of antiphospholipid syndrome: Going beyond thrombosis	9
Tackling the unknowns in understanding and management of hospital acquired anemia	9
Systematic review of staging bone marrow involvement in B cell lymphoma by flow cytometry	9
Artificial intelligence in sickle disease	9
Allogeneic hematopoietic stem cell transplant for sickle cell disease: The why, who, and what	8
Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML	8
Multipotent mesenchymal stromal cells in kidney transplant recipients: The next big thing?	8
Chronic graft-versus-host disease in pediatric patients: Differences and challenges	8
The association between excess body weight at diagnosis and pediatric leukemia prognosis: A systematic review and meta-analysis	8
Does PTCY increase the risk of infections?	8
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)	8
Not all LGL leukemias are created equal	8
SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapies	8
Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas	8
Primary and secondary immune thrombocytopenia (ITP): Time for a rethink	8
Chasing leukemia differentiation through induction therapy, relapse and transplantation	8
Putting function back in dysfunction: Endothelial diseases and current therapies in hematopoietic stem cell transplantation and cellular therapies	8
Diffuse large B-cell lymphoma: Time to focus on circulating blood nucleic acids?	8
CHIPing away the progression potential of CHIP: A new reality in the making	8
Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues	7
State-of-the-art review on AL amyloidosis in Western Countries: Epidemiology, health economics, risk assessment and therapeutic management of a rare disease	7
Biochemical marker research in hemophilic arthropathy: A systematic review	7
Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma	7
TP53 in AML and MDS: The new (old) kid on the block	7
Iron deficiency anemia among women: An issue of health equity	7
Thalassemia and autoimmune diseases: Absence of evidence or evidence of absence?	7
Recent advances in neutropenic enterocolitis: Insights into the role of gut microbiota	7
Relapse after allogeneic transplantation with post-transplant cyclophosphamide: Shattering myths and evolving insight	7
Haploidentical bone marrow transplants with post transplant cyclophosphamide on day + 3 + 5: The Genova protocol	7
Follow-up issues in survivors of hematologic malignancies – Current stance and future perspectives	7

Platelet factor 4(PF4) and its multiple roles in diseases	7
Immunity reloaded: Deconstruction of the PD-1 axis in B cell lymphomas	7
Knowing the unknowns in high risk multiple myeloma	7